Available carbapenems: properties and differences

被引:0
作者
Fresnadillo Martinez, Maria Jose [1 ]
Garcia Garcia, Maria Inmaculada [2 ]
Garcia Sanchez, Enrique [1 ]
Garcia Sanchez, Jose Elias [1 ,2 ]
机构
[1] Univ Salamanca, Fac Med, Microbiol, E-37008 Salamanca, Spain
[2] Univ Hosp, Microbiol Serv, Salamanca, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2010年 / 28卷
关键词
Carbapenems; Doripenem; Clinical use; Resistance;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Carbapenems are beta-lactam antibiotics endowed with a broader spectrum, activity and resistance to beta-lactamases than other beta-lactams. Due to their qualities, these antibiotics are crucial in empirical therapy, in the monotherapy of several severe hospital-acquired infections -and even that of some community-acquired infections as well as in the directed therapy of infections due to multiresistant Gram-negative bacteria. All the available carbapenems have a similar spectrum, although there are significant differences in their antimicrobial activity, which in the long run determines the clinical indications of each carbapenem. The spectrum of ertapenem does not cover eminently nosocomial pathogens such as Pseudomonas aeruginosa and Acinetobacter spp., and hence this antibiotic is indicated in community-acquired infections requiring hospital treatment. In contrast, doripenem shows greater intrinsic activity than other carbapenems in extended spectrum beta-lactamase-producing enterobacteria and AmpC P. aeruginosa, Acinetobacter spp. and other non-fermentative and anaerobic microorganisms. Additionally, like the remaining carbapenems, doripenem has adequate pharmacokinetic characteristics and a favorable safety profile. (c) 2010 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:53 / 64
页数:12
相关论文
共 78 条
  • [1] [Anonymous], 17 EUR C CLIN MICR I
  • [2] CONJUGAL TRANSFER OF IMIPENEM RESISTANCE IN BACTEROIDES-FRAGILIS
    BANDOH, K
    WATANABE, K
    MUTO, Y
    TANAKA, Y
    KATO, N
    UENO, K
    [J]. JOURNAL OF ANTIBIOTICS, 1992, 45 (04) : 542 - 547
  • [3] Comparative in vitro antimicrobial activity of a new carbapenem, doripenem:: tentative disc diffusion criteria and quality control
    Brown, SD
    Traczewski, MM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) : 944 - 949
  • [4] Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents
    Carmeli, Y
    Troillet, N
    Eliopoulos, GM
    Samore, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) : 1379 - 1382
  • [5] Spread of OXA-48-Positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey
    Carrer, Amelie
    Poirel, Laurent
    Eraksoy, Haluk
    Cagatay, A. Atahan
    Badur, Selim
    Nordmann, Patrice
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (08) : 2950 - 2954
  • [6] Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira, Mariana
    Jones, Ronald N.
    Livermore, David M.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (04) : 426 - 433
  • [7] Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study
    Chastre, Jean
    Wunderink, Richard
    Prokocimer, Philippe
    Lee, Michael
    Kaniga, Kone
    Friedland, Ian
    [J]. CRITICAL CARE MEDICINE, 2008, 36 (04) : 1089 - 1096
  • [8] In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis
    Chen, YH
    Garber, E
    Zhao, QQ
    Ge, YG
    Wikler, MA
    Kaniga, K
    Saiman, L
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) : 2510 - 2511
  • [9] Clinical and Laboratory Standards Institute, 2009, M100S19 CLSI S, pM100
  • [10] CLSI, 2008, M100S18 CLSI S